The Role of Anticonvulsant Drugs in Anxiety Disorders: A Critical Review of the Evidence

  title={The Role of Anticonvulsant Drugs in Anxiety Disorders: A Critical Review of the Evidence},
  author={Marco Mula and Stefano Pini and Giovanni Battista Cassano},
  journal={Journal of Clinical Psychopharmacology},
Antiepileptic drugs (AEDs) have been successfully used in the treatment of mood disturbances, leading clinicians and researchers to investigate their use in other psychiatric disorders. This article reviews the literature about the potential efficacy of AEDs in anxiety disorders. An updated MEDLINE search (January 1970 to September 2006) using the terms "panic disorder," "agoraphobia," "posttraumatic stress disorder," "obsessive-compulsive disorder," "generalized anxiety disorder," "social… 

Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review

Anticonvulsant and antipsychotic medications in the pharmacotherapy of panic disorder: a structured review

Some atypical antipsychotic and anticonvulsant medications may have a role in the treatment of some PD patients, mostly when more conventional approaches have not been successful, but the quality of supporting evidence is limited.

Non-Antidepressant Treatment of Generalized Anxiety Disorder.

Pregabalin and quetiapine are the two most promising non-antidepressant treatments for GAD.

Current pharmacological interventions in panic disorder.

Recent data indicate that augmentation strategies with aripiprazole, olanzapine, pindolol or clonazepam may be effective and D-cycloserine is a promising agent in the augmentation of cognitive behavioral therapy.

Pregabalin for the Treatment of Generalized Anxiety Disorder

Pregabalin rapidly relieves anxiety and offers another treatment option in patients who do not respond to or who suffer intolerable adverse effects from other agents, suggesting that pregabalin is effective and well tolerated in the treatment of GAD.

Anxiety disorders: a comprehensive review of pharmacotherapies.

There is evidence from multiple randomized, placebo-controlled trials and meta-analyses of pharmacological treatments of anxiety disorders to support the use of selective serotonin reuptake inhibitors as first-line pharmacotherapy in these disorders, and a number of them have received US Food and Drug Administration approval for these indications.

Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options

A lack of randomized double-blind placebo- controlled trials for anxiety disorders and few studies comparing novel treatments to existing anxiolytic agents suggests that there needs to be further expansion in research of these novel pathways and larger-scale studies of promising agents with positive results from smaller trials.

Pharmacological treatment for generalized anxiety disorder in adults: an update

Based on the evidence available to us, it is recommended that along with the ADs, benzodiazepines be considered a possible first-line therapy in eligible patients based on the discretion and clinical judgment of the treating physician.

Anksiyete Bozukluklarinin Tedavisinde Antiepileptik İlaçlarin Kullanimi Antiepileptic Drugs in the Treatment of Anxiety Disorders

This article focuses on recent literature to show the potential use of antiepileptic drugs in patients suffering from generalized anxiety Disorder, social anxiety disorder, posttraumatic stres disorder, panic disorder along with a brief review of neuroanatomic structures and neurotransmitters associated with epilepsy and anxiety disorders.

New approaches to the pharmacological management of generalized anxiety disorder

Quetiapine is a promising molecule for GAD treatment but its use would be complicated by long-term metabolic side effects and future research will have the objective to find more targeted molecules for the treatment of this disorder in light of its specific etiology.



Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders.

The testable hypothesis that better psychiatric outcomes in seizure disorder patients could be achieved is suggested by treating patients with baseline "activated" profiles with "sedating" predominantly GABAergic drugs, and conversely those with baseline 'sedated' or anergic profiles with 'activating' predominantly antiglutamatergic agents.

Carbamazepine in obsessive-compulsive disorder

Psychiatric adverse events during vigabatrin therapy.

Vigabatrin use in treatment-refractory partial epilepsy is associated with increased occurrence of depression and of psychosis, although the frequency of psychosis is apparently lower than previously reported.

Psychiatric Syndromes Related to Antiepileptic Drugs

All antiepileptic drugs may provoke positive or negative psychiatric reactions in individual patients. These psy‐chotropic effects are not simply idiosyncratic but depend on the drug's anticonvulsive

Anticonvulsants in anxiety disorders

Past and current research being done in the novel area of psychopharmacology is reviewed, indicating a potential role for anticonvulsants in the treatment of anxiety as monotherapy or augmentation therapy; however, these early findings must be supported by additional investigation in large-scale, placebo-controlled studies.

A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder

Gabapentin in the Treatment of Posttraumatic Stress Disorder.

  • T. Berigan
  • Psychology, Medicine
    Primary care companion to the Journal of clinical psychiatry
  • 2000
A patient diagnosed with posttraumatic stress disorder (PTSD) who had been taking multiple medications with little clinical response was placed on gabapentin treatment with beneficial results, and noted a distinct reduction in nightmares and flashbacks, and his depression improved.

An open-label study of levetiracetam for the treatment of social anxiety disorder.

This pilot study supports the safety and potential efficacy of a novel agent, levetiracetam, for the treatment of social anxiety disorder and warrants systematic evaluation as a treatment option for anxiety disorders.

Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment

Findings suggest a possible role for the SGRI tiagabine in the treatment of PTSD as the role of GABAergic drugs in PTSD is poorly defined and larger, randomized, double-blind, placebo-controlled trials are needed.

Treatment of posttraumatic stress disorder with phenytoin: an open-label pilot study.

Findings suggest that phenytoin may be efficacious in the treatment of PTSD, possibly mediated through its antiglutamatergic effects.